IGA NEPHROPATHY (IGAN)
Clinical trials for IGA NEPHROPATHY (IGAN) explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY (IGAN) trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New shot aims to slow kidney damage in IgA patients
Disease control Recruiting nowThis study tests an experimental drug called RG002C0106 in 30 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug safely reduces protein in the urine, a sign of kidney damage. Participants will receive either the drug or a…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
New hope for kidney patients: early budesonide may slow IgA nephropathy
Disease control Recruiting nowThis study tests whether starting budesonide capsules early can help people with IgA nephropathy, a kidney disease. About 200 adults will take the medicine and be monitored for 12 months to see if protein in urine decreases and kidney function stays stable. The goal is to control…
Matched conditions: IGA NEPHROPATHY (IGAN)
Sponsor: Sichuan Provincial People's Hospital • Aim: Disease control
Last updated May 26, 2026 08:20 UTC
-
New hope for kidney patients: avacopan combo trial launches
Disease control Recruiting nowThis study tests whether the drug avacopan, combined with a low-dose steroid, can help people with a severe form of IgA nephropathy (a kidney disease). The goal is to reduce protein in the urine and protect kidney function. The trial involves 16 adults whose kidney disease is at …
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug ADX-038 aims to control kidney disease in phase 2 trial
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system, such as IgA nephropathy and C3G. The goal is to see if the drug is safe and can help control the disease. Participants must have active kidney disease and be on…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Recruiting nowThis early-stage study is testing a new treatment for people with certain autoimmune diseases like lupus and kidney disease. The treatment uses specially engineered immune cells (CAR T-cells) that target and attack faulty immune cells causing the disease. The main goal is to chec…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New drug aims to slow kidney damage in IgA nephropathy patients
Disease control Recruiting nowThis study tests a new tablet called HSK39297 for people with IgA Nephropathy, a kidney disease. The goal is to see if it can lower protein in the urine and help protect kidney function over time. About 370 adults will take either the drug or a placebo for up to 104 weeks to chec…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Engineered immune cells aim to tame autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-219C, which uses specially engineered immune cells (CAR-T cells) to target and destroy faulty B cells that cause autoimmune diseases like lupus and kidney disease. The treatment involves a one-time infusion after a short chem…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated May 08, 2026 12:02 UTC